Welcome to our dedicated page for APOLLOMICS news (Ticker: APLMW), a resource for investors and traders seeking the latest updates and insights on APOLLOMICS stock.
Apollomics Inc. develops clinical-stage oncology therapies for difficult-to-treat and treatment-resistant cancers. Company news centers on vebreltinib (APL-101), a selective c-Met inhibitor for non-small cell lung cancer and other tumors with c-Met alterations, along with broader pipeline work in targeted therapy and immuno-oncology.
Recurring updates also cover financial results, clinical-development spending, development and commercialization arrangements, bridge and private financings, Nasdaq listing compliance, board and committee changes, litigation resolution, and operating-continuity matters tied to the company’s biotechnology development model.
Apollomics Inc. (Nasdaq: APLM) announced a private placement financing of approximately $6 million through subscription agreements for a PIPE financing, with gross proceeds to fund pipeline programs and general corporate purposes. The financing involves the sale of 19,166,666 Class A ordinary shares at $0.30 per share, expected to close on May 8, 2024. Additionally, Dr. Robert Lin, M.D., Ph.D., an experienced physician and researcher, has been appointed to the board of directors, while Jonathan Wang, Ph.D., has resigned. Canaccord Genuity acts as the financial advisor for the financing.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.